Trial Profile
A Phase 1, Randomized, Dose-escalation Study to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine at Two Dose Levels of the ID93 Antigen and the GLA-SE Adjuvant in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs ID 93 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 19 Feb 2018 According to an Aeras media release, follow up data from this study will be presented at 5th Global Forum on Tuberculosis 2018.
- 13 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.